The rheumatoid arthritis drug Xeljanz saw revenues jump 33% for the year, with total revenues coming in at $1.8 billion in 2018 https://t.co/E7KHJSgkjF
Links:
Jan-31-2019
Search for Terms or Answers
Search for Terms or Answers
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
